OBJECTIVES: To measure healthcare costs for patients receiving repaglinide, metformin, repaglinide/metformin, and glyburide/metformin within a managed care organization (MCO). METHODS: Using retrospective pharmacy and medical claims from a MCO, adult patients with type 2 diabetes identified during CY2000 were stratified into the following cohorts based on their medication regimen at identification date: repaglinide only (n = 500), metformin only (n = 26,535), repaglinide/metformin (n = 172), glyburide/metformin (n = 17,160). Pharmacy, medical, and total (pharmacy + medical) healthcare costs were measured for each cohort over a 9-month period. Costs were adjusted for age, gender, and comorbidities using Analysis of Covariance. RESULTS: Adjusted pharmacy costs were lowest for patients receiving metformin only ($1182; 95% CI $1172-$1191), followed by metformin/glyburide ($1339; 95% CI $1327-$1351), repaglinide only ($1518; 95% CI $1447-$1588), and repaglinide/metformin ($1936; 95% CI $1816 95% CI $ -$2056. Differences between the cohorts in adjusted medical and total healthcare costs were not statistically significant. Adjusted medical charges were $6988 for repaglinide/metformin, $8236 for metformin/glyburide, $8267 for metformin only, and $10,392 for repaglinide only. Total adjusted healthcare costs were lowest for repaglinide/metformin ($8924), followed by metformin only ($9448), metformin/glyburide ($9576), and repaglinide only ($11,910). CONCLUSIONS: Although not statistically significant, repaglinide/metformin yielded lower total healthcare costs than metformin alone, metformin/glyburide, or repaglinide alone. While these results need to be confirmed using larger patient populations, they imply that differences in pharmacy costs of repaglinide/metformin therapy are offset by measurable medical cost savings.
Ĺ OBJECTIVES: Limited data are available on treatment cost of diabetes Type 2 patients in Poland. The Cost Of Diabetes Type 2 In Poland (CODIP) is a multicenter, bottom-up designed, retrospective study aimed at evaluation of total cost of diabetes type 2 in Poland. Preliminary data on direct cost are presented. METHODS: Patients diagnosed with type 2 diabetes mellitus were randomly selected from outpatients' charts databases and surveyed with CODE-2 trial questionnaires adjusted to Polish setting. Both patient and practitioner questionnaires collected data from each patient on: clinical characteristic, medical and other resources used, quality of life. Total treatment costs were calculated using drug retail and medical procedures prices. Values are expressed in USD value (PPP¢2001 1 PLN = 1,98). RESULTS: 303 patients from 24 centers were included. Mean age 61.0 (95% CI: 59.8; 62.2); time from diagnosis 10.9 (10.0; 11.7); 74.6% patients presented comorbidities with coronary arteries disease as most prevalent (20.5%). The total annual treatment costs amounted to 4390 PLN (2127 USD). The cost structure: 13.7% physicians consultations, 2.2% paramedics, 25.6% diabetic drug costs (insulin 62.8%, oral hypoglycemic agents and glucagon 37.2%), hospital costs 35.7%, emergency service 0.6%. CONCLUSIONS: Economic impact of diabetes Type 2 in Poland is considerable. Insulin prescription patterns are responsible for large part of drug costs.
PDB23
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The NAVIGATOR trial will evaluate the impact of nateglinide and valsartan on the progression to diabetes in subjects with impaired glucose tolerance at risk for cardiovascular events. It is well documented that physician/site characteristics influence outcomes and resource utilization in health economic analyses. However, these characteristics are usually unknown in the international clinical trial setting. OBJECTIVES: We developed an approach to profile investigators and sites in multinational clinical trials by administering a survey during the site recruitment phase of the NAVIGATOR trial. We hypothesized that characteristics would vary geographically. METHODS: Survey items were developed based on a literature review and clinicians' input. Simple statistics were used to describe the sample. ANOVA and c 2 tests were used to test for differences across geographic regions. RESULTS: We received 528 investigator surveys representing a response rate of 60% and 96% for US and non-US countries, respectively. Eighty percent of investigators were male and the mean age was 48 years. Forty percent were endocrinologists, 39% internists, and 20%
